Nuclera extends Series C funding to $87M to advance antibody engineering
The funding will accelerate development of eProtein Discovery for full-format antibody expression, purification, and binding validation
19 Jan 2026
Nuclera has announced a USD $12 million financing extension, bringing the company’s total Series C funding to USD $87 million. The investment will accelerate the integration of antibody expression and binding validation capabilities into the Company’s eProtein Discovery benchtop system, which enables multiplex protein screening, characterization, and expression in-house.
Expanding eProtein Discovery with antibody-specific capabilities represents a strategic step as Nuclera moves into AI-enabled protein engineering, addressing a critical industry need for scalable, standardized, and high-quality datasets that can be used to power next-generation AI models in biologics discovery.
The advancement will enable researchers to perform end-to-end expression, purification, and binding validation of full-format antibodies on an integrated, high-throughput system.
Combining unique cell-free expression systems, novel digital microfluidics, and robust screening data, eProtein Discovery provides clear guidance on which protein has the best chance of success early on, thereby reducing the time, cost, and uncertainty traditionally associated with protein expression and purification.
Dr Michael Chen, CEO and co-founder, Nuclera, said, “This financing underscores our growing momentum and demonstrates that we are expanding eProtein Discovery into one of the fastest-growing segments of biologics R&D. Scientists increasingly require scalable, high-quality datasets to power AI models in biologics discovery. We are positioning Nuclera to become a foundational platform for the future of protein and antibody engineering, ultimately accelerating therapeutic discovery timelines.”